Philip D Home
Overview
Explore the profile of Philip D Home including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1979
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hollander P, Carofano W, Lam R, Golm G, Eldor R, Crutchlow M, et al.
Diabetes Obes Metab
. 2018 May;
20(9):2229-2237.
PMID: 29761615
Aim: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM). Materials And Methods: This Phase 3, randomized,...
12.
Home P, Ahren B, Reusch J, Rendell M, Weissman P, Cirkel D, et al.
Diabetes Res Clin Pract
. 2017 Jul;
131:49-60.
PMID: 28683300
Aims: Diabetes therapies that provide durable glycaemic control for people with type 2 diabetes mellitus (T2DM) are needed. We present efficacy results of albiglutide, a glucagon-like peptide-1 receptor agonist, in...
13.
Home P, Bergenstal R, Bolli G, Ziemen M, Rojeski M, Espinasse M, et al.
Diabetes Obes Metab
. 2017 Jun;
20(1):121-128.
PMID: 28661585
Aims: Insulin glargine 300 U/mL (Gla-300) offers a flatter pharmacodynamic profile than insulin glargine 100 U/mL (Gla-100). We have compared these insulins over 1 year in people with type 1...
14.
15.
Giorgino F, Home P, Tuomilehto J
Diabetes Care
. 2016 Jul;
39 Suppl 2:S187-95.
PMID: 27440832
The overall impact of glucose lowering on vascular complications and major clinical outcomes, including mortality, in type 2 diabetes is still an open issue. While intensive glucose control has undoubted...
16.
Riddle M, Bolli G, Home P, Bergenstal R, Ziemen M, Muehlen-Bartmer I, et al.
Diabetes Technol Ther
. 2016 Feb;
18(4):252-7.
PMID: 26840338
Background: Insulin glargine 300 U/mL (Gla-300) has a more constant and prolonged action profile than insulin glargine 100 U/mL and in clinical studies is associated with similar glycemic control but...
17.
Cefalu W, Bray G, Home P, Garvey W, Klein S, Pi-Sunyer F, et al.
Diabetes Care
. 2015 Oct;
38(8):1567-82.
PMID: 26421334
As obesity rates increase, so too do the risks of type 2 diabetes, cardiovascular disease, and numerous other detrimental conditions. The prevalence of obesity in U.S. adults more than doubled...
18.
Home P, Bergenstal R, Bolli G, Ziemen M, Rojeski M, Espinasse M, et al.
Diabetes Care
. 2015 Jun;
38(12):2217-25.
PMID: 26084341
Objective: Insulin therapy in type 1 diabetes still provides suboptimal outcomes. Insulin glargine 300 units/mL (Gla-300), with a flatter pharmacodynamic profile compared with insulin glargine 100 units/mL (Gla-100), is an...
19.
Home P, Dain M, Freemantle N, Kawamori R, Pfohl M, Brette S, et al.
Diabetes Res Clin Pract
. 2015 Apr;
108(2):350-9.
PMID: 25825361
Aims: It is of interest to understand how insulin therapy currently evolves in clinical practice, in the years after starting insulin in people with type 2 diabetes. We aimed to...
20.
Balkau B, Calvi-Gries F, Freemantle N, Vincent M, Pilorget V, Home P
Diabetes Res Clin Pract
. 2015 Mar;
108(3):432-40.
PMID: 25818885
Aims: To identify factors associated with glucose control, as measured by HbA1c over 4 years, in people with type 2 diabetes starting insulin therapy. Methods: CREDIT, an observational cohort study,...